[DOI] [PMC free article] [PubMed] [Google Scholar] 14.Zamudio-Cuevas Y., Martnez-Flores K., Martnez-Nava G.A., Clavijo-Cornejo D., Fernndez-Torres J., Snchez-Snchez R
New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
In this context, GSH and SSG influence apoptotic sensitivity in a context-dependent manner by regulating mitochondrial integrity and death signaling through redox-dependent mechanisms (Fig
CormeraisYGiulianoSLeFlochRFrontBDurivaultJTambutteEet al
cagrilintide vs
View Full Study Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia
